Shanta Chawla

919 total citations · 1 hit paper
15 papers, 702 citations indexed

About

Shanta Chawla is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Shanta Chawla has authored 15 papers receiving a total of 702 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Shanta Chawla's work include Neutropenia and Cancer Infections (5 papers), Histone Deacetylase Inhibitors Research (4 papers) and Blood disorders and treatments (3 papers). Shanta Chawla is often cited by papers focused on Neutropenia and Cancer Infections (5 papers), Histone Deacetylase Inhibitors Research (4 papers) and Blood disorders and treatments (3 papers). Shanta Chawla collaborates with scholars based in United States, South Korea and Hungary. Shanta Chawla's co-authors include Gajanan Bhat, Poul Knoblauch, Francine M. Foss, Lee F. Allen, Jeanette K. Doorduijn, Kerry J. Savage, Peter de Nully Brown, Georg Heß, Andrei R. Shustov and Achiel Van Hoof and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Shanta Chawla

15 papers receiving 693 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

2015 386 citations Owen A. O’Connor, Steven M. Horwitz et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Shanta Chawla

Since Specialization

Citations

This map shows the geographic impact of Shanta Chawla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shanta Chawla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shanta Chawla more than expected).

Fields of papers citing papers by Shanta Chawla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shanta Chawla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shanta Chawla. The network helps show where Shanta Chawla may publish in the future.

Co-authorship network of co-authors of Shanta Chawla

This figure shows the co-authorship network connecting the top 25 collaborators of Shanta Chawla. A scholar is included among the top collaborators of Shanta Chawla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shanta Chawla. Shanta Chawla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Abstract PS9-59: Pooled efficacy analysis from two phase 3 studies in patients receiving eflapegrastim, a novel, long-acting granulocyte-colony stimulating factor, following TC for early-stage breast cancer 2021 ·Cancer Research ·Lee S. Schwartzberg, Gajanan Bhat, Alvaro Restrepo, (unknown), Inderjit Mehmi, Yong Wha Moon, Seung Jae Baek, Shanta Chawla, François Lebel, Patrick Cobb	1
2	Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia after Same-Day Dosing of Eflapegrastim in Patients with Breast Cancer Receiving Docetaxel and Cyclophosphamide (NCT04187898) 2020 ·Blood ·Lee S. Schwartzberg, (unknown), (unknown), Manuel Modiano, (unknown), Shanta Chawla, Gajanan Bhat, François Lebel, Nishan Tchekmedyian	1
3	A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study 2020 ·Cancer Medicine ·Patrick Cobb, Yong Wha Moon, (unknown), István Láng, Gajanan Bhat, Shanta Chawla, (unknown), Lee S. Schwartzberg	19
4	Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial 2020 ·The Oncologist ·Lee S. Schwartzberg, Gajanan Bhat, Julio A. Peguero, Richy Agajanian, (unknown), Alvaro Restrepo, (unknown), Inderjit Mehmi, Shanta Chawla, (unknown), Zane Yang, Patrick Cobb	22
5	Justification for a Fixed Dose of Eflapegrastim, a Long‐Acting G‐CSF, in Patients Receiving Docetaxel‐Cyclophosphamide Chemotherapy 2020 ·The Journal of Clinical Pharmacology ·John Barrett, Douglas S. Greene, Sribalaji Lakshmikanthan, (unknown), Shanta Chawla, François Lebel	1
6	クエン酸塩前駆体ゾル‐ゲル法を用いて合成したCo‐Zrドーピングによるナノ結晶ストロンチウムヘキサフェライトの物理化学的,磁気,マイクロ波および電磁的性質の調節【Powered by NICT】 2017 ·Ceramics International ·(unknown), Shanta Chawla, Sher Singh Meena, S. M. Yusuf, Kunal Pubby, (unknown)	1
7	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study breakdown → 2015 ·Journal of Clinical Oncology ·Owen A. O’Connor, Steven M. Horwitz, Tamás Masszi, Achiel Van Hoof, Peter de Nully Brown, Jeanette K. Doorduijn, Georg Heß, Wojciech Jurczak, Poul Knoblauch, Shanta Chawla, Gajanan Bhat, Mi Rim Choi, Jan Walewski, Kerry J. Savage, Francine M. Foss, Lee F. Allen, Andrei R. Shustov	386
8	Study of growth of dot and column in porous silicon samples of various thicknesses prepared at a constant current density 2015 ·Physica E Low-dimensional Systems and Nanostructures ·Fateh Singh Gill, Varij Panwar, (unknown), (unknown), Shanta Chawla, (unknown), R.M. Mehra	2
9	A Phase II trial of Belinostat ( PXD 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma 2014 ·British Journal of Haematology ·Francine M. Foss, Ranjana H. Advani, Madeleine Duvic, Kenneth B. Hymes, Tanin Intragumtornchai, Arnuparp Lekhakula, Ofer Shpilberg, Adam Lerner, Robert J. Belt, Eric D. Jacobsen, Guy Laurent, Dina Ben‐Yehuda, M. Beylot‐Barry, Uwe Hillen, Poul Knoblauch, Gajanan Bhat, Shanta Chawla, Lee F. Allen, Brad Pohlman	161
10	Abstract CT207: Pharmacokinetic analysis of the HDAC inhibitor belinostat (PXD-101) and metabolites in patients with hepatic dysfunction 2014 ·Cancer Research ·Brian F. Kiesel, Robert A. Parise, Yan Lin, Deborah Allen, (unknown), Shanta Chawla, Richard Piekarz, Percy Ivy, (unknown), Jan H. Beumer	1
11	Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma 2013 ·Journal of Hematology & Oncology ·Peter Reimer, Shanta Chawla	16
12	Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial. 2013 ·Journal of Clinical Oncology ·Owen A. O’Connor, Tamás Masszi, Kerry J. Savage, Lauren Pinter‐Brown, Francine M. Foss, Leslie Popplewell, Amanda F. Cashen, Jeanette K. Doorduijn, Shanta Chawla, Poul Knoblauch, Pier Luigi Zinzani, Peter de Nully Brown, Georg Heß, Achiel Van Hoof, Steven M. Horwitz, Andrei R. Shustov	46
13	Pharmacokinetics of SPI-1620 in a Phase I, open label, ascending dose study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the endothelin B receptor agonist, SPI-1620, in recurrent or progressive carcinoma 2013 ·Life Sciences ·(unknown), Anthony W. Tolcher, Anil Gulati, Shanta Chawla, Lee F. Allen	6
14	Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer 2006 ·The Journal of Urology ·Rajiv Puri, Victor Palit, Paul M. Loadman, (unknown), Tariq Shah, (unknown), (unknown), John A. Double, (unknown), Shanta Chawla, M. Beer, (unknown), Richard de Boer, Jos H. Beijnen, Christopher Twelves, Roger M. Phillips	37
15	Phase I/II clinical evaluation of intravesical EOquin (EO9) against superficial bladder cancer 2005 ·Cancer Research ·Roger M. Phillips, Paul M. Loadman, (unknown), (unknown), Victor Palit, (unknown), (unknown), Luigi Lenaz, Shanta Chawla, (unknown), Rajiv Puri	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact